Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01023477 · ClinicalTrials.gov registry record · Phase 1
Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)
A Phase 1 study, sponsored by Inova Health Care Services.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01023477 is a Phase 1 study that has completed, run by Inova Health Care Services. The registered enrollment target is 12 participants.
The verdict
NCT01023477, a Phase 1 study, has completed, sponsored by Inova Health Care Services.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to test the hypothesis that chloroquine will reduce the ability of ductal carcinoma in situ (DCIS) to survive and spread. Participants will receive either chloroquine standard dose (500mg/week) or chloroquine low dose (250mg/week) for 1 month prior to surgical removal of the tumor.
Interventions
- PROCEDURE Breast Biopsy
- DRUG Chloroquine Standard Dose (500mg/week)
- DRUG Chloroquine Low Dose (250mg/week)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-12 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01023477
The ClinicalTrials.gov registry entry for NCT01023477 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inova Health Care Services, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Breast Biopsy is the first listed.
NCT01023477 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01023477 about?
NCT01023477 is a clinical study titled "Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)". The purpose of this study is to test the hypothesis that chloroquine will reduce the ability of ductal carcinoma in situ (DCIS) to survive and spread. Participants will receive either chloroquine standard dose (500mg/week) or chloroquine low dose (250mg/week) for 1 month prior to surgical removal of...
What is the current status of trial NCT01023477?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2009-12. Estimated completion is 2016-10.
What interventions are being tested in trial NCT01023477?
The interventions under investigation include: Breast Biopsy (PROCEDURE), Chloroquine Standard Dose (500mg/week) (DRUG), Chloroquine Low Dose (250mg/week) (DRUG).
Who is sponsoring clinical trial NCT01023477?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.